The PROTAC market is witnessing substantial momentum owing to the growing demand for next-generation targeted therapeutics capable of degrading disease-causing proteins previously considered “undruggable.” Rising investments in oncology research, rapid advances in targeted protein degradation (TPD) technologies, and increasing clinical success of